Form 4: Werewolf Therapeutics CFO Timothy Trost Acquires Stock Options

Chief Financial Officer of Werewolf Therapeutics, Timothy W. Trost, reports acquisition of stock options.

Summary

• On January 2, 2025, Timothy W. Trost, the Chief Financial Officer of Werewolf Therapeutics, Inc., acquired stock options.
• Trost acquired options to purchase 150,000 shares of common stock at an exercise price of $1.56.
• These options vest in equal monthly installments over four years, starting one month after the Vesting Commencement Date of January 1, 2025, and continuing through January 1, 2029.
• Trost also acquired options to purchase 60,358 shares of common stock at an exercise price of $1.56.
• These options expire on December 31, 2034.
• Following the transaction, Trost directly owns options for 210,358 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of stock options by an executive is generally viewed as a positive sign, but it's not a strong indicator of future performance.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

There are no explicit forward-looking statements in this document.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry.
• The vesting schedule of four years is fairly standard.
• The exercise price of $1.56 would need to be compared to the current market price of HOWL to determine the potential value to the executive.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates